Date: 2017-04-20
Type of
information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at The International Liver Congress
Company: Neurovive Pharmaceutical (Sweden)
Product: NV556
Action
mechanism:
- cyclophilin inhibitor. NV556 is a potent cyclophilin inhibitor in NeuroVive’s Sangamide class of compounds. The first preclinical results for the effects of NV556 on fibrosis development in an experimental model of NASH were received during the autumn of 2016.
Disease: NASH (non-alcoholic steatohepatitis)
Therapeutic
area: Liver diseases - Hepatic diseases
Country:
Trial
details:
Latest
news:
- • On April 20, 2017, NeuroVive Pharmaceutical announced positive preclinical results demonstrating anti-fibrotic effects with NV556, the company’s preclinical compound for non-alcoholic steatohepatitis (NASH), in an additional well-validated experimental NASH model. NV556 has previously shown similar anti-fibrotic effects in the experimental STAM™ NASH model. NeuroVive’s scientists present novel data demonstrating anti-fibrotic effects of NV5556 also in the experimental MCD NASH model, strengthening and confirming the previous findings. In addition, in the STAM model where NASH is followed by liver cancer development, long term treatment with NV556 was well tolerated and significantly reduced liver weight increase, indicating a reduced tumor burden. Furthermore, there was a trend that NV556 reduced both the number and the size of tumors on the liver surface.
- These data have been presented at The International Liver Congress™ taking place in Amsterdam (poster: “Anti-fibrotic effect of NV556, a sanglifehrin-based cyclophilin inhibitor, in a preclinical model of non-alcoholic steatohepatitis”).
In addition to NV556, NeuroVive is developing a new class of compounds with a different mode of action. This project is complementary to NV556 and may offer an alternative treatment opportunity of NASH patients. This discovery project, titled NVP022, utilizes NeuroVive’s core competence in mitochondrial energy regulation, and NeuroVive’s partner company Isomerase’s innovative chemistry capabilities are providing chemical compounds currently undergoing experimental concept testing.
Is
general: Yes
